Breast cancer drug that can extend lives approved for NHS use

Joy as deal struck to make Kadcyla, which costs an annual £90,000 per patient at full price, available for routine use

A drug that can extend the lives of women with advanced breast cancer has been approved for routine use on the NHS.

Charities and campaigners reacted with huge disappointment when the National Institute for Health and Care Excellence (Nice) rejected the drug, Kadcyla, on cost grounds in 2016.

Related: New therapy offers hope against incurable form of breast cancer

Related: Testicular cancer: men most at risk could be identified using new gene group

Continue reading…

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us